Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysis

Journal article


Publication Details

Author(s): Fasching P, Hartkopf AD, Gaß P, Häberle L, Akpolat-Basci L, Hein A, Volz B, Taran FA, Nabieva N, Pott B, Overkamp F, Einarson H, Hadji P, Tesch H, Ettl J, Lueftner D, Wallwiener M, Mueller V, Janni W, Fehm TN, Schneeweiss A, Untch M, Pott D, Lux MP, Geyer T, Liedtke C, Seeger H, Wetzig S, Hartmann A, Schulz-Wendtland R, Belleville E, Wallwiener D, Beckmann M, Brucker SY, Kolberg HC
Journal: Breast Cancer Research and Treatment
Publication year: 2019
Volume: 173
Journal issue: 2
Pages range: 319-328
ISSN: 0167-6806


Abstract

PurposeNeoadjuvant combination treatment with chemotherapy (CTX), trastuzumab (TZM), and pertuzumab (PTZ) has been shown to result in higher pathological complete response rates (pCR) in comparison with treatment with chemotherapy and trastuzumab (CTX/TZM). This analysis was aimed at real-world validation of these results from prospective randomized trials.MethodsIn a retrospective analysis conducted in the PRAEGNANT network, patients were eligible for inclusion if they had either received neoadjuvant therapy with CTX/TZM or chemotherapy, trastuzumab, and pertuzumab (CTX/TZM/PTZ) and subsequently underwent surgery for their primary breast cancer. The effect of the two neoadjuvant regimens on pCR in addition to commonly applicable predictors of pCR was analyzed in 300 patients from three study sites, using logistic regression analyses with treatment arm, age, clinical tumor stage, grading, and hormone receptor status as predictors.ResultspCR with complete disappearance of all tumor cells was seen in 30.2% (n=58) of patients treated with CTX/TZM and in 52.8% (n=57) of those treated with CTX/TZM/PTZ. CTX/TZM/PTZ was positively associated with pCR (adjusted odds ratio 2.44; 95% CI 1.49-4.02). Mastectomy rates were not influenced by the therapy.ConclusionsThe results of clinical trials were confirmed in this dataset of patients who were treated outside of clinical trials in everyday routine work. pCR rates can be improved by 20% with pertuzumab in routine clinical use.


FAU Authors / FAU Editors

Beckmann, Matthias Prof. Dr.
Lehrstuhl für Geburtshilfe und Frauenheilkunde
Fasching, Peter PD Dr.
Professur für Translationale Frauenheilkunde und Geburtshilfe
Gaß, Paul Dr. med.
Frauenklinik
Geyer, Thomas
Frauenklinik
Hartmann, Arndt Prof. Dr. med.
Lehrstuhl für Allgemeine Pathologie und Pathologische Anatomie
Hein, Alexander PD Dr.
Frauenklinik
Nabieva, Naiba Dr. med.
Frauenklinik


External institutions with authors

Centrum für Hämatologie und Onkologie Bethanien
Charité - Universitätsmedizin Berlin
ClinSol GmbH & Co.KG
Eberhard Karls Universität Tübingen
HELIOS Kliniken
Marienhospital Bottrop
Oncologianova GmbH
Ruprecht-Karls-Universität Heidelberg
Technische Universität München (TUM)
Universitätsklinikum Düsseldorf
Universitätsklinikum Hamburg-Eppendorf (UKE)
Universitätsklinikum Heidelberg
Universitätsklinikum Ulm


How to cite

APA:
Fasching, P., Hartkopf, A.D., Gaß, P., Häberle, L., Akpolat-Basci, L., Hein, A.,... Kolberg, H.-C. (2019). Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysis. Breast Cancer Research and Treatment, 173(2), 319-328. https://dx.doi.org/10.1007/s10549-018-5008-3

MLA:
Fasching, Peter, et al. "Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysis." Breast Cancer Research and Treatment 173.2 (2019): 319-328.

BibTeX: 

Last updated on 2019-22-03 at 10:08